Abstract
This review examines the growing literature on the role of peroxisome proliferator-activated receptors (PPARs) in addiction. There are two subtypes of PPAR receptors that have been studied in addiction: PPAR-α and PPAR-γ. The role of each PPAR subtype in common models of addictive behavior, mainly pre-clinical models, is summarized. In particular, studies are reviewed that investigated the effects of PPAR-α agonists on relapse, sensitization, conditioned place preference, withdrawal and drug intake, and effects of PPAR-γ agonists on relapse, withdrawal and drug intake. Finally, studies that investigated the effects of PPAR agonists on neural pathways of addiction are reviewed. Taken together these preclinical data indicate that PPAR agonists are promising new medications for drug addiction treatment.
Keywords: Self-administration, abuse, dependence, stress, nuclear receptors, opioids, nicotine, alcohol, psychostimulants, PPAR.
Current Drug Targets
Title:Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence
Volume: 14 Issue: 7
Author(s): Bernard Le Foll, Patricia Di Ciano, Leigh V. Panlilio, Steven R. Goldberg and Roberto Ciccocioppo
Affiliation:
Keywords: Self-administration, abuse, dependence, stress, nuclear receptors, opioids, nicotine, alcohol, psychostimulants, PPAR.
Abstract: This review examines the growing literature on the role of peroxisome proliferator-activated receptors (PPARs) in addiction. There are two subtypes of PPAR receptors that have been studied in addiction: PPAR-α and PPAR-γ. The role of each PPAR subtype in common models of addictive behavior, mainly pre-clinical models, is summarized. In particular, studies are reviewed that investigated the effects of PPAR-α agonists on relapse, sensitization, conditioned place preference, withdrawal and drug intake, and effects of PPAR-γ agonists on relapse, withdrawal and drug intake. Finally, studies that investigated the effects of PPAR agonists on neural pathways of addiction are reviewed. Taken together these preclinical data indicate that PPAR agonists are promising new medications for drug addiction treatment.
Export Options
About this article
Cite this article as:
Foll Bernard Le, Ciano Patricia Di, Panlilio Leigh V., Goldberg Steven R. and Ciccocioppo Roberto, Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence, Current Drug Targets 2013; 14 (7) . https://dx.doi.org/10.2174/1389450111314070006
DOI https://dx.doi.org/10.2174/1389450111314070006 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exosomes and Exosomal microRNAs in Age-associated Stroke
Current Vascular Pharmacology The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design Incretins, Pregnancy, and Gestational Diabetes
Current Pharmaceutical Biotechnology “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Pain and Child: A Translational Hypothesis on the Pathophysiology of a Mild Type-2 Diabetes Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic Basis, Nutritional Challenges and Adaptive Responses in the Prenatal Origin of Obesity and Type-2 Diabetes
Current Diabetes Reviews Mechanisms of Dexamethasone-Induced Hypertension
Current Hypertension Reviews Neuronal Histamine and its Receptors: Implication of the Pharmacological Treatment of Obesity
Current Medicinal Chemistry Nesfatin-1; Implication in Stress and Stress-associated Anxiety and Depression
Current Pharmaceutical Design Sleep Loss and Hypertension: A Systematic Review
Current Pharmaceutical Design Ciclesonide: A Closer Look at its Systemic and Oropharyngeal Safety Profile
Current Drug Safety Retinoic Acid and the Gut Microbiota in Alzheimer’s Disease: Fighting Back-to-Back?
Current Alzheimer Research Pro-Inflammatory Cytokines: New Potential Therapeutic Targets for Obesity-Related Bone Disorders
Current Drug Targets The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design Tualang Honey and its Methanolic Fraction Improve LPS-induced Learning and Memory Impairment in Male Rats: Comparison with Memantine
Current Nutrition & Food Science Fighting Alzheimer's Disease and Type 2 Diabetes: Pathological links and Treatment Strategies
CNS & Neurological Disorders - Drug Targets Melanocortins and their Receptors and Antagonists
Current Drug Targets Beta-Blockers: Effects on Bone Mineral Density and Fracture Risk
Current Rheumatology Reviews Role of the Hippocampus and Amygdala in the Extinction of Fear- Motivated Learning
Current Neurovascular Research